Mechanism of action<unk>  is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of<unk>  to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.
Ramucirumab
Ustekinumab
Emapalumab
Olaratumab
Evolocumab
Avelumab
Anifrolumab
Burosumab